Analyzing the Clonality Profile in Myeloproliferative Neoplasms and Thrombotic Risks

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study focuses on patients diagnosed with Myeloproliferative Neoplasms (MPN) to investigate the relationship between the JAK2V617F allele burden in various cell types and the risk of thrombotic complications. It aims to measure the allele burden in platelets, red blood cells, granulocytes, and endothelial cells to identify high-risk clonality profiles. By isolating these cells from 120 patients, the study seeks to establish reliable biomarkers for predicting thrombotic risk in MPN patients.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Adult patient (age ≥ 18 years)
* Inclusion at diagnosis or during the year following the diagnosis of PV or ET (2016 WHO criteria except bone marrow biopsy that is optional), before introduction of a cytoreductive treatment
* Patient carrying a JAK2V617F mutation
* Subject registered with a social security scheme
* Written informed consent obtained
* Acceptance of inclusion in the FIMBANK registry (specific consent form needed)

Exclusion Criteria:

* ET or PV Patient not carrying a JAK2V617F mutation
* Patient with cytoreductive treatment (hydroxyurea, anagrelide, interferon, ruxolitinib or other chemotherapy) at the time of blood sampling
* Person under judicial safeguards, trustee or curatorship
* Person unable to give her consent
* Non-cooperative person
* Exclusion period after another clinical study or participation to another clinical study in the 30 days before inclusion

Where it's running

• CHU d'Angers, Service Maladies du Sang
  Angers, France Recruiting
• CH de Bayonne, Service Hématologie Clinique
  Bayonne, France Recruiting
• CHU de Bordeaux, Service Médecine Interne et Maladies Infectieuses
  Bordeaux, France Recruiting
• Institut Bergonié, Service Hématologie Clinique
  Bordeaux, France Recruiting
• CHU de Brest, Service Hématologie Clinique
  Brest, France Recruiting
• CH de Dax, Service Hématologie Clinique
  Dax, France Recruiting

Study contacts

• Study coordinator: Olivier MANSIER
• Email: olivier.mansier@chu-bordeaux.fr
• Phone: 05 56 79 56 79

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Caris Chromoseq data collection for AML, MDS, and MPN

  This study tests how well the Caris Chromoseq assay helps categorize risk in patients with AML, MDS, or MPN compared with standard tests.

  Recruiting Caris Science, Inc. · Phoenix, Arizona · NCT07680868

• Using NETosis blood markers to predict clot risk in JAK2-positive myeloproliferative neoplasms

  This study will try to see if blood markers of NETosis can predict clotting risk in people with JAK2V617F-positive myeloproliferative neoplasms who are at high risk for thrombosis.

  Recruiting University Hospital, Bordeaux · Angers and 14 other locations · NCT07119970

• CMV Triplex vaccine to boost immunity and prevent CMV after haploidentical stem cell transplant

  This trial tests whether giving a CMV-MVA Triplex vaccine to donors and/or recipients, with or without the antiviral letermovir, can boost CMV immunity and prevent CMV viremia in people having haploidentical stem cell transplants.

  Recruiting at 3 sites Phase 1 City of Hope Medical Center · Duarte, California and 2 other locations · NCT07020533

• Vedolizumab with post-transplant cyclophosphamide and short-course tacrolimus to prevent graft-versus-host disease after reduced-intensity allogeneic stem cell transplant

  This trial tests whether adding vedolizumab to post-transplant cyclophosphamide and a short course of tacrolimus can prevent graft-versus-host disease in adults getting reduced-intensity allogeneic stem cell transplants for leukemias or related blood disorders.

  Recruiting Phase 2 City of Hope Medical Center · Duarte, California · NCT06815003

• Study of characteristics and complications in young patients with myeloproliferative neoplasia

  This study is trying to gather information about young people under 30 with myeloproliferative neoplasia to better understand their health and complications.

  Recruiting University Hospital, Brest · Brest · NCT06715267

• Using Sorafenib to Prevent Relapse After Stem Cell Transplantation

  This study is testing if the drug sorafenib can help prevent relapse in patients with high-risk blood cancers after they receive a stem cell transplant.

  Recruiting Phase 2 St. Petersburg State Pavlov Medical University · Saint Petersburg · NCT06532084

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.